Fragment-Based Drug Discovery Market to Reach USD 3.2 Billion by 2035, Driven by Advances in Structural Biology and Novel Drug Discovery Technologies

The global fragment-based drug discovery (FBDD) market was valued at US$ 1.1 Bn in 2024 and is projected to grow at a CAGR of 10.6% from 2025 to 2035, crossing US$ 3.2 Bn by the end of 2035. Increasing pharmaceutical R&D investment, demand for novel therapeutic targets, and advances in structural biology are accelerating the adoption of FBDD across pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic institutions.

Gain an understanding of key findings from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741

Market Overview: Fragment-based drug discovery is an advanced drug design approach that identifies small molecular-weight chemical fragments as starting points for developing therapeutic candidates. Unlike conventional high-throughput screening, which evaluates large compound libraries, FBDD uses smaller and chemically diverse fragments that can efficiently explore chemical space.

Although individual fragments may exhibit relatively weak binding affinity, structural biology and medicinal chemistry enable researchers to grow, link, or optimize these fragments into potent and selective drug candidates. NMR spectroscopy, X-ray crystallography, cryo-electron microscopy, mass spectrometry, surface plasmon resonance, and computational modeling are increasingly integrated into FBDD workflows.

The approach is particularly valuable for challenging targets, including protein-protein interactions, allosteric pockets, membrane proteins, RNA targets, and other biological mechanisms that have historically been difficult to address using conventional discovery methods.

Key Drivers of Market Growth

High Efficiency and Versatility of FBDD

The efficiency and flexibility of FBDD are major factors supporting market expansion. Smaller fragment libraries can cover chemical space effectively while requiring fewer compounds to screen than conventional libraries. This can reduce early-stage discovery complexity and provide valuable starting points for medicinal chemistry programs.

FBDD also enables researchers to modify fragments through systematic growing, linking, and optimization. Its compatibility with structural and computational techniques allows scientists to obtain detailed insights into target binding and accelerate design-make-test cycles.

Innovations in Fragment Libraries

Advances in fragment library design are expanding the range of targets accessible through FBDD. Modern libraries increasingly emphasize chemical diversity, three-dimensional structures, drug-like physicochemical properties, and specialized chemistries.

Covalent fragments, electrophile-tuned fragments, natural-product-inspired structures, RNA-targeting fragments, and computationally designed libraries are creating new opportunities. Artificial intelligence and machine learning are also being applied to predict fragment performance and prioritize compounds for screening, potentially improving hit identification and reducing discovery timelines.

Key Players and Industry Leaders

The competitive landscape is increasingly focused on integrated platforms rather than individual drug-discovery assets. Leading companies are combining fragment libraries, automated biophysical screening, structural biology, computational chemistry, medicinal chemistry, and rapid synthesis capabilities.

Prominent players operating in the global market include Thermo Fisher Scientific Inc., Astex Pharmaceuticals, Domainex, Beactica Therapeutics AB, Charles River Laboratories, Evotec International GmbH, Sprint Bioscience, Structure Based Design, Inc., Sygnature Discovery Limited, Malvern Panalytical Ltd., Vernalis (R&D) Limited (HitGen Inc.), SARomics Biostructures, WuXi AppTec, Schrödinger, Inc., and ZOBIO BV.

Companies are pursuing partnerships, CRO collaborations, risk-sharing discovery agreements, option-to-license arrangements, and technology development initiatives to strengthen their FBDD capabilities.

Access detailed insights by visiting our full report - https://www.transparencymarketresearch.com/fragment-based-drug-discovery-market.html

Key Trends for the Future

One of the most important trends is the increasing integration of structural biology with computational drug design. High-field NMR, synchrotron X-ray crystallography, microcrystal X-ray techniques, serial crystallography, and cryo-EM are improving the speed and quality of fragment-hit validation.

Another emerging trend is the use of physics-informed computational approaches, including water thermodynamics and free-energy calculations, to guide fragment optimization. Native mass spectrometry, SPR, and MST are also being combined to characterize weak binders and understand binding mechanisms.

FBDD is additionally expanding beyond traditional small-molecule targets toward macrocycles, molecular glues, protein degraders, RNA targets, and challenging allosteric sites.

New Opportunities and Challenges

The market presents significant opportunities as pharmaceutical and biotechnology companies seek first-in-class mechanisms and differentiated therapeutic candidates. Growing interest in oncology, CNS disorders, immunology, infectious diseases, and metabolic diseases is creating demand for discovery platforms capable of addressing difficult targets.

Data integration represents another opportunity. Enterprise data lakes, electronic laboratory notebooks, FAIR data standards, and integrated structure-activity relationship datasets can improve decision-making and accelerate iterative discovery cycles.

However, FBDD also faces challenges. Fragment hits can have weak affinity, requiring sensitive detection technologies and extensive optimization. Structural characterization can require sophisticated infrastructure and specialized expertise. The cost of high-field NMR, crystallography, cryo-EM, and advanced computational platforms may also limit adoption among smaller organizations.

Buy this Premium Research Report to access comprehensive analysis - https://www.transparencymarketresearch.com/checkout.php?rep_id=4741<ype=S

Market Segmentation

The fragment-based drug discovery market can be segmented as follows:

By Product Type: Fragment Libraries, Screening Technologies, Software Tools

By Technique: Biophysical Techniques, NMR Spectroscopy, X-ray Crystallography, Mass Spectrometry, Capillary Electrophoresis, and Others including Fluorescence Polarization and Surface Plasmon Resonance; Non-Biophysical Techniques

By Application: Oncology, Central Nervous System Disorders, Infectious Diseases, Cardiovascular Diseases, Metabolic Disorders, and Others including Inflammation and Autoimmune Diseases

By End User: Contract Research Organizations, Pharmaceutical and Biotechnology Companies, and Academic & Research Institutions

By Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Important FAQs

How big was the global fragment-based drug discovery market in 2024?

The global fragment-based drug discovery market was valued at US$ 1.1 Bn in 2024.

How big will the market be by 2035?

The global fragment-based drug discovery market is projected to cross US$ 3.2 Bn by 2035.

What is driving the growth of the FBDD market?

Major growth factors include rising pharmaceutical R&D investment, high efficiency of fragment screening, innovations in fragment libraries, advances in structural biology, and increasing demand for novel therapeutic mechanisms.

What will be the CAGR during 2025–2035?

The market is projected to expand at a 10.6% CAGR during the forecast period.

Who are the prominent players in the market?

Key companies include Thermo Fisher Scientific, Astex Pharmaceuticals, Domainex, Charles River Laboratories, Evotec, Sygnature Discovery, WuXi AppTec, Schrödinger, and other specialized FBDD and drug-discovery providers.

What is the future of fragment-based drug discovery?

The future is expected to be shaped by AI-assisted fragment design, advanced structural biology, covalent and allosteric discovery, integrated biophysical screening, automated synthesis, and expansion into challenging targets such as RNA, molecular glues, and protein degraders.

More Related Reports –

Medical Enzyme Technology Market: https://www.transparencymarketresearch.com/medical-enzymes-technology.html

Bone Marrow Aspirate Concentrates Market: https://www.transparencymarketresearch.com/bone-marrow-aspirate-concentrates-market.html

Antimicrobial Ingredients Market: https://www.transparencymarketresearch.com/antimicrobial-ingredients-market.html

Recombinant Proteins Market: https://www.transparencymarketresearch.com/recombinant-proteins-market.html

About Us Transparency Market Research:

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analyzed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com

Sales Inquiries: sales@transparencymarketresearch.com